BRAF and chronic myelogenous leukemia, BCR-ABL1 positive: Several studies have shown that targeting various molecular alterations of interest in specific tumor types can improve outcomes, including EGFR, ALK, ROS1 or BRAF V600E in non-small-cell lung cancer [5,6,7,8], BRAF V600E in melanoma [9], BCR-ABL in chronic myeloid leukemia [10], or RET in medullary thyroid cancer [11].